Gilead Sciences Inc (GILD): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Gilead ( GILD) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.6%. By the end of trading, Gilead rose 91 cents (2.2%) to $42.45 on light volume. Throughout the day, six million shares of Gilead exchanged hands as compared to its average daily volume of 9.4 million shares. The stock ranged in a price between $41.60-$42.49 after having opened the day at $41.66 as compared to the previous trading day's close of $41.54. Other companies within the Health Care sector that increased today were: USMD Holdings ( USMD), up 18.9%, Edap TMS ( EDAP), up 18.3%, pSivida ( PSDV), up 18.3%, and Onyx Pharmaceuticals ( ONXX), up 12%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Gilead has a market cap of $63.46 billion and is part of the drugs industry. The company has a P/E ratio of 21.5, above the S&P 500 P/E ratio of 17.7. Shares are up 14% year to date as of the close of trading on Thursday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, increase in net income, growth in earnings per share and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, Oxygen Biotherapeutics ( OXBT), down 33%, CombiMatrix Corporation ( CBMX), down 21.9%, EnteroMedics ( ETRM), down 19.6%, and Merit Medical Systems ( MMSI), down 15.2%, were all laggards within the health care sector with Humana ( HUM) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.